Epidemiology and treatment of pulmonary arterial hypertension

Nature Reviews Cardiology

Volumn 14, Issue 10, 2017, Pages 603-614

  Lau, Edmund M T ^a   Giannoulatou, Eleni ^b,c   Celermajer, David S ^a,d   Humbert, Marc ^e,f,g  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e BICÊTRE HOSPITAL   (France)

^f Universite Paris Sud   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BARDOXOLONE; BESTATIN; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CREATININE; FUMARIC ACID DIMETHYL ESTER; ILOPROST; IRON; MACITENTAN; PLACEBO; PROSTACYCLIN; RIOCIGUAT; RITUXIMAB; SELEXIPAG; SILDENAFIL; TADALAFIL; TOCILIZUMAB; TREPROSTINIL; ANTIHYPERTENSIVE AGENT;

AGE; BMPR2 GENE; CONGENITAL HEART DISEASE ASSOCIATED PULMONARY ARTERIAL HYPERTENSION; CONNECTIVE TISSUE DISEASE ASSOCIATED PULMONARY ARTERIAL HYPERTENSION; CREATININE BLOOD LEVEL; DIFFUSING CAPACITY FOR CARBON MONOXIDE; GENDER; GENE; GENE MUTATION; HEART OUTPUT; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; NEW YORK HEART ASSOCIATION CLASS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVERALL SURVIVAL; OXYGEN CONSUMPTION; PERICARDIAL EFFUSION; PORTAL HYPERTENSION; PORTOPULMONARY HYPERTENSION; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; REVIEW; SEX DIFFERENCE; SIX MINUTE WALK TEST; SURVIVAL RATE; SYSTEMIC SCLEROSIS; TRICUSPID ANNULAR PLANE SYSTOLIC EXCURSION; COMBINATION DRUG THERAPY; MOLECULARLY TARGETED THERAPY; PROCEDURES; PROGNOSIS; RISK FACTOR; SEX FACTOR; TRANSLATIONAL RESEARCH;

AGE FACTORS; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION, PULMONARY; MOLECULAR TARGETED THERAPY; PROGNOSIS; RISK FACTORS; SEX FACTORS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85032695764     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2017.84     Document Type: Review

References (116)

1. Humbert, M. et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43, 13S-24S (2004).
2. Humbert, M. et al. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 130, 2189-2208 (2014).
3. Tonelli, A. R. et al. Causes and circumstances of death in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 188, 365-369 (2013).
4. Vonk-Noordegraaf, A. et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J. Am. Coll. Cardiol. 62, D22-D33 (2013).
5. Simonneau, G. et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 62, D34-D41 (2013).
6. Galie, N. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Respir. J. 46, 903-975 (2015).
7. Hoeper, M. M. et al. Definitions and diagnosis of pulmonary hypertension. J. Am. Coll. Cardiol. 62, D42-50 (2013).
8. Peacock, A. J. et al. An epidemiological study of pulmonary arterial hypertension. Eur. Respir. J. 30, 104-109 (2007).
9. Humbert, M. et al. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 173, 1023-1030 (2006).
10. Ling, Y. et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am. J. Respir. Crit. Care Med. 186, 790-796 (2012).
11. Strange, G. et al. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart 98, 1805-1811 (2012).
12. D'Alonzo, G. E. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 115, 343-349 (1991).
13. Rich, S. et al. Primary pulmonary hypertension. A national prospective study. Ann. Intern. Med. 107, 216-223 (1987).
14. Humbert, M. et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122, 156-163 (2010).
15. Thenappan, T. et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur. Respir. J. 30, 1103-1110 (2007).
16. Thenappan, T. et al. Survival in pulmonary arterial hypertension: A reappraisal of the NIH risk stratification equation. Eur. Respir. J. 35, 1079-1087 (2010).
17. Badesch, D. B. et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 137, 376-387 (2010).
18. Benza, R. L. et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 142, 448-456 (2012).
19. Escribano-Subias, P. et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur. Respir. J. 40, 596-603 (2012).
20. Jiang, X., Humbert, M. & Jing, Z. C. in Pulmonary Vascular Disorders Vol. 41 (eds Humbert, M., Souza, R. & Simonneau, G.) 85-93 (Karger, 2012).
21. Jing, Z. C. et al. Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 132, 373-379 (2007).
22. Hoeper, M. M. et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int. J. Cardiol. 168, 871-880 (2013).
23. Ogawa, A. et al. Survival of Japanese patients with idiopathic/heritable pulmonary arterial hypertension. Am. J. Cardiol. 119, 1479-1484 (2017).
24. Chung, W. J. et al. Baseline characteristics of the Korean Registry of Pulmonary Arterial Hypertension. J. Korean Med. Sci. 30, 1429-1438 (2015).
25. Jansa, P. et al. Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: A retrospective analysis of a nationwide registry. BMC Pulm. Med. 14, 45 (2014).
26. Alves, J. L. Jr et al. Pulmonary arterial hypertension in the southern hemisphere: results from a registry of incident Brazilian cases. Chest 147, 495-501 (2015).
27. Mueller-Mottet, S. et al. Long-term data from the Swiss pulmonary hypertension registry. Respiration 89, 127-140 (2015).
28. Zhang, R. et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest 140, 301-309 (2011).
29. Lee, W. T. et al. Predicting survival in pulmonary arterial hypertension in the UK. Eur. Respir. J. 40, 604-611 (2012).
30. McGoon, M. D. et al. Pulmonary arterial hypertension: epidemiology and registries. J. Am. Coll. Cardiol. 62, D51-D59 (2013).
31. Hoeper, M. M. & Simon, R. G. J. The changing landscape of pulmonary arterial hypertension and implications for patient care. Eur. Respir. Rev. 23, 450-457 (2014).
32. Poms, A. D. et al. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: A REVEAL registry analysis. Chest 144, 169-176 (2013).
33. Halpern, S. D. & Taichman, D. B. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest 136, 37-43 (2009).
34. Larkin, E. K. et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 186, 892-896 (2012).
35. Benza, R. L. et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 141, 354-362 (2012).
36. Kawut, S. M. et al. Sex and race differences in right ventricular structure and function: The multi-ethnic study of atherosclerosis-right ventricle study. Circulation 123, 2542-2551 (2011).
37. Jacobs, W. et al. The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension. Chest 145, 1230-1236 (2014).
38. Sitbon, O. et al. Initial dual oral combination therapy in pulmonary arterial hypertension. Eur. Respir. J. 47, 1727-1736 (2016).
39. Gall, H. et al. The Giessen Pulmonary Hypertension Registry: survival in pulmonary hypertension subgroups. J. Heart Lung Transplant. http:// dx.doi.org/10.1016/j.healun.2017.02.016 (2017).
40. Benza, R. L. et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122, 164-172 (2010).
41. Evans, J. D. et al. BMPR2 mutations and survival in pulmonary arterial hypertension: An individual participant data meta-analysis. Lancet Respir. Med. 4, 129-137 (2016).
42. Montani, D. et al. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: A population-based study. Lancet Respir. Med. 5, 125-134 (2017).
43. Tamby, M. C. et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 60, 765-772 (2005).
44. Humbert, M. et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur. Respir. J. 36, 549-555 (2010).
45. Sitbon, O. et al. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur. Respir. J. 46, 152-164 (2015).
46. Giaid, A. et al. Expression of endothelin1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328, 1732-1739 (1993).
47. Giaid, A. & Saleh, D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 333, 214-221 (1995).
48. Humbert, M., Sitbon, O. & Simonneau, G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 351, 1425-1436 (2004).
49. Guignabert, C. et al. New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication. Chest 147, 529-537 (2015).
50. Morrell, N. W. et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-1 and bone morphogenetic proteins. Circulation 104, 790-795 (2001).
51. Humbert, M. et al. Increased interleukin1 and interleukin6 serum concentrations in severe primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 151, 1628-1631 (1995).
52. Price, L. C. et al. Inflammation in pulmonary arterial hypertension. Chest 141, 210-221 (2012).
53. Perros, F. et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 185, 311-321 (2012).
54. McMurtry, M. S. et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ. Res. 95, 830-840 (2004).
55. Zhao, L. et al. Heterogeneity in lung 18FDG uptake in pulmonary arterial hypertension: potential of dynamic 18FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments. Circulation 128, 1214-1224 (2013).
56. Perros, F. et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 178, 81-88 (2008).
57. Tu, L. et al. Autocrine fibroblast growth factor2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. 45, 311-322 (2011).
58. Guignabert, C. et al. Pathogenesis of pulmonary arterial hypertension: lessons from cancer. Eur. Respir. Rev. 22, 543-551 (2013).
59. Yuan, J. X. et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 98, 1400-1406 (1998).
60. Antigny, F. et al. Potassium channel subfamily K member 3 (KCNK3) contributes to the development of pulmonary arterial hypertension. Circulation 133, 1371-1385 (2016).
61. Machado, R. D. et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am. J. Hum. Genet. 68, 92-102 (2001).
62. Ma, L. et al. A novel channelopathy in pulmonary arterial hypertension. N. Engl. J. Med. 369, 351-361 (2013).
63. Soubrier, F. et al. Genetics and genomics of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 62, D13-D21 (2013).
64. Humbert, M. & Ghofrani, H. A. The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax 71, 73-83 (2016).
65. Galie, N. et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N. Engl. J. Med. 373, 834-844 (2015).
66. Davie, N. et al. ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am. J. Respir. Crit. Care Med. 165, 398-405 (2002).
67. Hirata, Y. et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J. Clin. Invest. 91, 1367-1373 (1993).
68. Rubin, L. J. et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896-903 (2002).
69. Humbert, M. et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur. Respir. J. 30, 338-344 (2007).
70. Galie, N. et al. Ambrisentan therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 46, 529-535 (2005).
71. Galie, N. et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117, 3010-3019 (2008).
72. Iglarz, M. et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 327, 736-745 (2008).
73. Pulido, T. et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N. Engl. J. Med. 369, 809-818 (2013).
74. Rybalkin, S. D. et al. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ. Res. 93, 280-291 (2003).
75. Galie, N. et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353, 2148-2157 (2005).
76. Rubin, L. J. et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: The SUPER2 study. Chest 140, 1274-1283 (2011).
77. Galie, N. et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119, 2894-2903 (2009).
78. Stasch, J. P. et al. NOindependent regulatory site on soluble guanylate cyclase. Nature 410, 212-215 (2001).
79. Stasch, J. P., Pacher, P. & Evgenov, O. V. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123, 2263-2273 (2011).
80. Ghofrani, H. A. et al. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 369, 330-340 (2013).
81. Humbert, M. et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT1 and PATENT2. Ann. Rheum. Dis. 76, 422-426 (2017).
82. Ghofrani, H. A. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N. Engl. J. Med. 369, 319-329 (2013).
83. Olschewski, H. et al. Cellular pathophysiology and therapy of pulmonary hypertension. J. Lab. Clin. Med. 138, 367-377 (2001).
84. Coleman, R. A., Smith, W. L. & Narumiya, S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46, 205-229 (1994).
85. Barst, R. J. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N. Engl. J. Med. 334, 296-301 (1996).
86. Sitbon, O. et al. EPITOME2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. Am. Heart J. 167, 210-217 (2014).
87. Jing, Z. C. et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: A randomized, controlled trial. Circulation 127, 624-633 (2013).
88. McLaughlin, V. V. et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial. J. Am. Coll. Cardiol. 55, 1915-1922 (2010).
89. Asaki, T. et al. Selexi: An oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. J. Med. Chem. 58, 7128-7137 (2015).
90. Sitbon, O. et al. Selexi: for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 373, 2522-2533 (2015).
91. European Medicines Agency. EMA concludes safety review of Uptravi. EMA http://www.ema.europa.eu/ ema/index.jspcurl=-pages/news-and-events/ news/2017/04/news-detail002726.jsp& mid=WC0b01ac058004d5c1 (2017).
92. Barst, R. J. et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54, S78-S84 (2009).
93. McLaughlin, V. V. et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 174, 1257-1263 (2006).
94. Hoeper, M. M. et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 28, 691-694 (2006).
95. Simonneau, G. et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Ann. Intern. Med. 149, 521-530 (2008).
96. Tapson, V. F. et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOMC study): A randomized controlled trial. Chest 142, 1383-1390 (2012).
97. Tapson, V. F. et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOMC2 study): A randomized controlled trial. Chest 144, 952-958 (2013).
98. McLaughlin, V. et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur. Respir. J. 46, 405-413 (2015).
99. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00323297 (2014).
100. Lajoie, A. C. et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: A meta-analysis. Lancet Respir. Med. 4, 291-305 (2016).
101. Galie, N. et al. PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur. Respir. J. 45, 1314-1322 (2015).
102. Humbert, M. et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE2. Eur. Respir. J. 24, 353-359 (2004).
103. Coghlan, J. G. et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue diseaseassociated pulmonary arterial hypertension (CTDPAH): subgroup analysis from the AMBITION trial. Ann. Rheum. Dis. http://dx.doi.org/10.1136/ annrheumdis-2016-210236 (2016).
104. Galie, N. et al. AMBITION: A randomised, multicentre study of first line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH). Eur. Respir. J. 44, A2916 (2014).
105. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02558231 (2016).
106. Hassoun, P. M. et al. Ambrisentan and tadalafil upfront combination therapy in scleroderma-associated pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 192, 1102-1110 (2015).
107. Sitbon, O. et al. Upfront triple combination therapy in pulmonary arterial hypertension: A pilot study. Eur. Respir. J. 43, 1691-1697 (2014).
108. Rosenkranz, S. et al. Left ventricular heart failure and pulmonary hypertension. Eur. Heart J. 37, 942-954 (2016).
109. Opitz, C. F. et al. Pre-capillary, combined, and post-capillary pulmonary hypertension: A pathophysiological continuum. J. Am. Coll. Cardiol. 68, 368-378 (2016).
110. Charalampopoulos, A. et al. Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. Pulm. Circ. 4, 669-678 (2014).
111. van Campen, J. S. et al. Bisoprolol in idiopathic pulmonary arterial hypertension: An explorative study. Eur. Respir. J. 48, 787-796 (2016).
112. Gomez-Arroyo, J. et al. Treatment for pulmonary arterial hypertension-associated right ventricular dysfunction. Ann. Am. Thorac Soc. 11, 1101-1115 (2014).
113. Mathai, S. C. et al. Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. J. Rheumatol. 38, 2410-2418 (2011).
114. Forfia, P. R. et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am. J. Respir. Crit. Care Med. 174, 1034-1041 (2006).
115. van Wolferen, S. A. et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur. Heart J. 28, 1250-1257 (2007).
116. van de Veerdonk, M. C. et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J. Am. Coll. Cardiol. 58, 2511-2519 (2011).